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ABSTRACT 
 
Characterization of a novel antigen of Mycobacterium tuberculosis K 
strain and its use in immunodiagnosis of tuberculosis 
 
Paul Jaewook Park 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Sang-Nae Cho) 
 
 
 
 
 
 Developing rapid and accurate methods for the diagnosis of 
Mycobacterium tuberculosis infection is a major priority in controlling the 
disease. The tuberculin skin test, in use for over a century, has remained 
virtually unchanged and is often complicated by those previously vaccinated 
against tuberculosis. Recently, assays evaluating a patient’s T-cell response to 
M. tuberculosis-specific antigens by measuring interferon- (IFN-levels 
have had promising results. Current methods use the highly immunogenic 
early-secreted protein ESAT-6 in combination with several other M. 
tuberculosis-specific antigens to elicit an immune response from patient 
leukocytes.  
 The Beijing family of M. tuberculosis accounts for nearly 50% of all 
infections in East Asia. In South Korea, a particular strain within this family, 
the K strain, has been shown to be predominant. Upon comparing the genome 
of the K strain with the common laboratory strain H37Rv, a K-specific 
insertion approximately 5.7 kb in size was identified. Within this insertion, 
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the sequence for an ESAT-6 like protein, insB, was found. The purpose of this 
study was to characterize the immunogenicity of the InsB protein. 
 The sequence for insB was cloned and expressed in E. coli 
BL21(DE3), and the recombinant protein was purified. Mice were immunized 
with either the ESAT-6 or InsB protein and ELISA was performed using 
serum samples from the immunized mice to evaluate the humoral response to 
the antigen. The T cell response was measured using flow cytometry to 
quantify the cytokine response of isolated splenocytes from the mice. ESAT-6 
and InsB were used to measure the antibody in tuberculosis (TB) patients as 
well. 
 A significant difference was seen in B cell response in mice prior to 
and following immunization with InsB. Splenocytes stimulated with InsB 
showed strong IFN-and IL-17 responses and a weak IL-2 response, all of 
which have been implicated in the diagnosis of tuberculosis. TB patients’ 
serum samples also showed a significant response to InsB when compared to 
healthy control samples. These results indicate a K strain-specific 
immunogenicity of InsB that could further improve upon current 
immunodiagnostic methods, especially for the South Korean population. 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: M. tuberculosis K strain, antigen, immunodiagnosis, ESAT-6, 
InsB 
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I. INTRODUCTION 
 
 Tuberculosis is a major infectious disease and its causative agent, 
Mycobacterium tuberculosis, currently infects about one third of the world’s 
population. According to the World Health Organization, there were 
approximately 8.8 million incident cases of tuberculosis with nearly 1.1 
million deaths due to the disease in 20101. Though a majority of those 
infected do not proceed to active disease, the organisms remain in a latent 
phase and can re-emerge if the immune system becomes weakened2. In order 
to control such a disease, rapid and accurate diagnosis of latent M. 
tuberculosis infection (LTBI) is needed for preventive therapy before 
reactivation.  
 
1. Identification of the K strain in South Korea 
 
 Over the years, several distinct strains of tuberculosis have 
developed. Restriction fragment length polymorphism (RFLP) analyses have 
been used to find unique polymorphism patterns that differ between strains. 
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The repetitive DNA element, IS6110, is a widely used standard for 
characterizing tuberculosis families3. The Beijing strain, an especially virulent 
strain, accounts for nearly 50% of infections in East Asia4. The Beijing strain 
has been linked with resistance to antibiotic treatments as well as increased 
virulence5. It has also been suggested that resistance to the Bacillus Calmette-
Guérin vaccine (BCG), the only approved vaccine for M. tuberculosis in the 
past century, has led to its selection; the Beijing strain has experienced an 
approximately 500-fold population increase over nearly two centuries6, 7.  
 In Korea, epidemiological studies have shown that one particular 
strain of the Beijing family, the K strain, is prevalent among TB patients 
within the country8,9. The K strain shares the characteristic IS6110 RFLP 
pattern unique to Beijing strains9. The K family strains, found more 
frequently during school outbreaks of TB in South Korea than other strains, 
are likely more efficient in transmission and were found to be more virulent 
in a mouse model of TB10. 
Considering the predominance of the K strain, in order to accurately 
detect tuberculosis infection in Korea, it is important to explore K strain-
specific biomarkers in order to increase the sensitivity of current diagnostic 
tools. 
 
2. Immunology of M. tuberculosis infection 
  
Upon entering the body, M. tuberculosis is contained by the host 
immune system in most cases. Uptake by macrophages leads to the formation 
of granulomas; complex structures involving macrophages, neutrophils, 
dendritic cells, B cells, T cells, and various other immunologic cells11. Within 
these granulomas, M. tuberculosis bacteria are able to persist indefinitely in a 
hypoxic state, while cytokines such as TNF- and IFN- work to contain the 
infection from re-activating12,13. In this state, disturbances in the immune 
system such as HIV infection, corticosteroid treatment, or aging, could lead to 
the release of bacteria and further spread to others14. 
 Considering that the bacteria persist mainly within macrophages, it is 
largely thought that CD4+ T cells are the principal component of the immune 
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response to infection. Various studies in animal models, as well as studies 
conducted in HIV-infected patients, reflect higher rates of infection in those 
with reduced T cell responses15,16,17 . The TH2 response and subsequent B cell 
response, though less studied, have also been suggested to play an important 
role in managing M. tuberculosis infection18. A major priority in finding a 
more effective method of diagnosis is exploring antigen markers that can 
distinguish these immune responses. 
 
3. Current methods of diagnosis  
 
 The tuberculin skin test (TST), which has been used to detect latent 
M. tuberculosis infection (LTBI) for nearly the past century, has much room 
for improvement in terms of sensitivity and specificity. The test, which 
evaluates delayed-type hypersensitivity of the patient’s cell-mediated immune 
response to tuberculosis antigens, is often complicated by those previously 
immunized with BCG19. Over the last several decades, new developments 
have changed the direction of tuberculosis diagnostics. First, assays that 
measure the antibody titer against M. tuberculosis specific antigens are in use 
today but are still being refined in order to increase diagnostic sensitivity20. 
Secondly, assays that measure the immune response of patient peripheral 
blood mononuclear cells (PBMC) to M. tuberculosis specific antigens ex vivo 
have already been widely adopted in detecting LTBI. Measuring the IFN- 
levels in response to stimulation by M. tuberculosis specific antigens has 
proven to be a more accurate, sensitive method to detect TB infections than 
TST21. 
 The current, widely used IFN- release assay (IGRA) diagnostic is 
known as the QuantiFERON-TB Gold assay. This kit requires incubation of 
whole blood with M. tuberculosis-specific antigens and measures the IFN- 
concentration by ELISA. The antigens used to stimulate the patient PBMC 
are two proteins secreted by M. tuberculosis known as ESAT-6 and CFP-
1022,23. The ESAT-6 and CFP-10 proteins are part of the ESX-1 secretion 
pathway, coded in the RD1 region of the M. tuberculosis genome.  It has been 
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shown that strains that lack these genes have a significant reduction in 
virulence24,25. In particular the M. tuberculosis K strain, when compared to 
other non-Beijing strains of M. tuberculosis such as H37Rv, shows a 
significant up-regulation of these two proteins26. These findings indicate that 
these two well-characterized antigens could play an important role in 
identifying K strain infections as well.  
 
4. Purpose 
 
 This study aims to characterize a K strain-specific ESAT-6 like 
protein, InsB, and to explore its potential in improving current 
immunodiagnostic methods. The completion of the genomic sequence of one 
of the most widely used laboratory strains of M. tuberculosis, H37Rv, has 
uncovered many new antigen candidates to explore27. Upon comparing the 
H37Rv and K strain genomic sequences, antigen candidates particular to the 
K strain were identified, among which insB was found. PCR was performed 
on the insB sequence and the recombinant protein was expressed in E. coli, 
purified and used to immunize BALB/c mice. ESAT-6 was also included in 
the study to compare the immunogenicity of the InsB protein with an 
established biomarker for tuberculosis. Splenocytes from immunized mice 
were stimulated using the antigens and their cytokine release levels were 
analyzed. The antigen candidates were also used for antibody detection in 
serum samples collected from immunized mice as well as TB patient serum 
samples acquired from Masan National Tuberculosis Hospital in Changwon, 
South Korea. The immunogenicity of the antigen candidates was analyzed 
through antibody titer levels using ELISA. By characterizing the 
immunogenic properties of InsB, we hope to improve both IFN- based and 
antibody-based diagnostics in South Korea. 
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II.   METHODS AND MATERIALS 
 
1. Selection of antigen candidates 
 
 Comparison of the partial genome sequences of the K and H37Rv 
strains revealed a 5.7 kb insertion found only in the K strain. The 
approximately 5.7 kb sequence, called the insertion region, coded for several 
proteins of interest found in the PPE protein region. The PE/PPE proteins are 
known to induce a strong immune response in the host and play an important 
role in the virulence and pathogenesis of M. tuberculosis28,29.  These protein 
sequences were then compared to those of established immunogenic antigen 
markers such as ESAT-6 and CFP-10. 
  
2. Cloning of antigen candidates 
 
 M. tuberculosis K strain was grown in Sauton media at 37℃. Its 
genomic DNA was prepared using N-acetyl-N,N,N-trimethyl ammonium 
bromide (CTAB) buffer as described by Somerville, et al30. Polymerase chain 
reaction (PCR) was performed to amplify the insB sequence. 50 ng K 
genomic DNA, 10x Pfu buffer (Solgent, Daejeon, Korea), 5x Band Doctor 
(Solgent, Daejeon, Korea), 2.5 mM dNTP (Solgent, Daejeon, Korea), 20 M 
each of forward and reverse primer (insB-F : 5'-
TTGCATATGACGATCAATTATCAGTTCGG-3' including NdeI site;   
insB-R : 5'-GCGGATCCAGCCCAGCTGGAACCCACT-3’ including 
BamHI site), and 1 ㎕ Pfu DNA polymerase (Solgent, Daejeon, Korea) were 
combined with distilled water for a final volume of 50 ㎕. Denaturation was 
performed at 94℃ for 5 minutes, annealing was performed at 50℃ for 30 
seconds, and amplification was performed at 72℃ for 30 seconds. The PCR 
product was confirmed on a 1.5% agarose gel and an Expin PCR SV 
purification kit was used (GeneAll, Seoul, Korea) according to 
manufacturer’s instructions. Sequences containing a 6  histidine tag were 
inserted into the pET11a_KB vector by incubating with NdeI and BamHI 


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enzymes (NEB, Ipswich, MA, USA) for 1 hour and 30 minutes at 37℃. After 
the addition of calf intestinal alkaline phosphatase (CIP), the DNA was 
incubated for an additional 30 minutes at 37℃. The DNA was run on a 1.5% 
agarose gel and the band was excised and extracted with an Expin Gel SV 
extraction kit (GeneAll, Seoul, Korea). The vector and DNA inserts were 
combined in a 1:5 ratio, and then incubated at 60℃ for 5 minutes. Next, 1 ㎕ 
10x T4 DNA ligase buffer (NEB, Ipswich, MA, USA), 1 ㎕ T4 DNA ligase 
(NEB, Ipswich, MA, USA) and distilled water were added for a final volume 
of 10 ㎕ and incubated for an hour at 25℃ to complete ligation.  
 A volume of 10 ㎕  DNA was transferred to 100 ㎕  of E. coli 
DH5and incubated on ice for 20 minutes. The cells were then heat shocked 
at 42℃ for 90 seconds, placed back on ice, 900 ㎕ Luria-Bertani (LB) broth 
was added, then the cells were placed in a 37℃ shaking incubator for one 
hour. The cells were spread onto LB agar plates with ampicillin (100 ㎍/㎖) 
and incubated at 37℃ overnight. Plasmids were then extracted using an 
Expin Plasmid purification kit (GeneAll, Seoul, Korea). 
 
 3. Expression and purification of antigen candidates 
 
 The recombinant protein was expressed in E. coli BL21(DE3). E. coli 
BL21(DE3) were transformed with 1 ㎕ DNA following the same protocol as 
for . coli D Cells were grown in LB broth containing 100 ㎍ /㎖ 
ampicillin at 37℃ for three hours until an OD600 of 0.6 ~ 0.7. 
Cells were then induced with 1 mM isopropyl-D-1-thiogalactoside 
(IPTG) and incubated again for 4 hours, after which cells were harvested and 
the pellet was sonicated in a 20 mM Tris buffer (pH 8.0). After centrifugation 
at 12,000 rpm for 30 minutes, the remaining inclusion bodies were prepared 
in a 20 mM Tris-HCl (pH 7.5) buffer containing 300 mM NaCl, 5 mM 
imidazole and 6 M urea. After centrifugation, Ni-NTA resin (Qiagen, Venlo, 
Netherlands) for histidine affinity purification was added to the supernatant 
and allowed to bind overnight at 4℃. The resin was then packed in a column 
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(Biorad, Hercules, CA, USA) for purification and washed with an identical 
buffer containing 30 mM imidazole. Elutions were performed using a similar 
Tris buffer containing 200 mM imidazole.  
 After affinity purification with Ni-NTA resin, fast protein liquid 
chromatography (FPLC) was used to further purify the recombinant proteins 
and to eliminate any other contaminants, including endotoxins. FPLC was 
performed using an ÄKTA-FPLC (GE, Pittsburgh, PA, USA) and a MonoQ 
anion exchange column (GE, Pittsburgh, PA, USA), in which the NaCl 
concentration in the Tris buffer was slowly increased to separate individual 
proteins. Following separation by FPLC, proteins were confirmed with SDS-
PAGE for purity. For refolding, samples underwent dialysis overnight at 4℃ 
in a buffer containing 20 mM Tris (pH 8.0), 20 mM -mercaptoethanol and 
5% glycerol. Samples were then transferred into a similar buffer without -
mercaptoethanol and again placed in 4 ℃  overnight while stirring. A 
bicinchoninic acid assay (BCA) was performed to quantify the recombinant 
protein. The assay was performed according to manufacturer’s instructions 
(Pierce, Rockford, IL, USA). Proteins then underwent gamma irradiation for 
sterilization prior to splenocyte stimulation.  
 
4. Immunization of mice 
 
 All mouse experiments were in accordance with IACUC guidelines. 
BALB/c mice, between 5~6 weeks old, were immunized with a dose of 20 ㎍ 
of target antigen emulsified with 250 ㎍  dimethyl dioctadecylammonium 
bromide (Sigma, St. Louis, MO, USA) and adjuvanted with 25 ㎍ 
monophospholipid A (Sigma, St. Louis, MO, USA)31. Five mice were in each 
immunization group. Control groups, containing four mice each, were 
injected with either saline or the adjuvant mix only.  
The injections (0.2 ㎖/mice) were given subcutaneously on the back 
three times, in two-week intervals. Serum samples were collected retro-
orbitally 3~4 days prior to the initial injection and two weeks following the 
last injection. Serum was placed at room temperature for 1 hour to allow 
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clotting, and then placed in 4℃ for two hours for further clotting. The sample 
was then centrifuged at 4,000 rpm for 20 minutes and the supernatant was 
transferred to a clean tube for storage at -20℃ until use. 
 
5. Detection of antibodies in mice 
 
Plates were coated overnight at 4 ℃  with InsB protein at a 
concentration of 5 ㎍/㎖ (ESAT-6 were coated at 2 ㎍/㎖) in coating buffer 
(0.5 M carbonate-bicarbonate buffer). After washing with PBST, plates were 
blocked with PBST with 5% NGS (PBST-NGS) and incubated at 37℃ for 1 
hour. The plates were then emptied and incubated with mouse serum samples 
diluted (1:2,000) in PBST-NGS for 2 hours at 37℃. The plates were washed 
with PBST, and peroxidase-conjugated anti-mouse IgG enzyme-labeled 
antibody (Merck, Darmstadt, Germany) diluted (1:10,000) in PBST-NGS was 
incubated for one hour at room temperature. The remaining procedure was 
identical to that of the human serum ELISA. 
 
6. Splenocyte stimulation and cytokine analysis 
 
 Spleens were removed from the mice two weeks after the last 
injection and passed through a 40 ㎛ cell strainer (BD Biosciences, San Jose, 
CA, USA). Cells were suspended in RPMI, which contained 5% fetal bovine 
serum and 1 unit/㎖ Antibiotic-Antimycotic (Invitrogen, Grand Island, NY, 
USA). The cells were spun down at 1,200 rpm for 5 minutes and the 
supernatant was discarded. 2 ㎖ ACK lysis buffer (0.15 M NH4Cl, 1 mM 
KHCO3, 0.1 mM Na2EDTA) was then added. After 5 minutes, 8 ㎖ RPMI 
was added and again spun down at 1,200 rpm for 5 minutes. The supernatant 
was discarded, 5 ㎖ RPMI was added, and again spun down. The supernatant 
was discarded and the cells were resuspended in a final volume of 1 ㎖ 
RPMI. A volume of 100 ㎕ containing 1 106 cells were plated in a 96-well 


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plate and stimulated with either RPMI with 10% FBS or the antigen 
candidates at a concentration of 5 ㎍/㎕. A positive control group of naïve 
mouse splenocytes were stimulated with concanavalin A. Cells were then 
incubated for 48 hours and the supernatant was collected and stored at -75℃. 
Flow cytometry was performed to quantify cytokine levels using a kit from 
eBioscience (San Diego, CA, USA) and a BD LSRII flow cytometer (San 
Jose, CA, USA). The concentration of each cytokine was calculated using 
FlowCytomix Pro software (eBioscience). 
 
7. Detection of antibodies in human serum samples  
 
 All TB patient samples were used according to an IRB-approved 
protocol. Serum samples were obtained from 86 TB patients and 40 healthy 
controls. Plates were coated with InsB protein at a concentration of 5 ㎍/㎖ 
(ESAT-6 coated at 2 ㎍/㎖), diluted in coating buffer (0.5 M carbonate-
bicarbonate buffer) and allowed to incubate overnight at 4℃. Plates were then 
washed with PBS with 0.05% Tween20 (PBST). Patient serum samples were 
diluted (1:300) in PBST containing 5% normal goat serum (PBST-NGS) and 
allowed to attach for 2 hours at 37℃. 
              The plates were washed and incubated again at 37 ℃  with a 
peroxidase-conjugated anti-human IgG enzyme-labeled antibody (Merck, 
Darmstadt, Germany) diluted (1:10,000) in PBST with 5% NGS. Plates were 
incubated at 37℃ for another hour. After several more washes the plates were 
visualized using tetramethylbenzidine (KPL, Gaithersburg, MD, USA) and 
the reaction was stopped with 2.5 N H2SO4. The absorbance was read at 
OD450. 
  
8. Statistical Analyses 
 
  Statistical calculations were performed using Graphpad Prism 5 
(Graphpad Software, La Jolla, CA, USA). Differences in B cell response for 
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non-immunized and immunized mice were analyzed using the paired 
Student’s T-test. Differences between human active tuberculosis patients and 
healthy control patients were calculated with the Mann-Whitney test. 
Differences were considered significant if P < 0.05. Diagnostic accuracy of 
each candidate was evaluated using receiver operating characteristic (ROC) 
curve analysis, which correlates true and false positive rates [sensitivity and 
(1-specificity)]. Differences in the area under the curve (AUC) values were 
calculated as well. 
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III.   RESULTS 
 
1. DNA sequencing 
 
Comparison of the K and H37Rv strain revealed several insertions 
found only in the K strain. The 5.7 kb insertion found in the PPE region 
contained a protein with only several amino acid differences compared to the 
ESAT-6 (Rv3875) protein of the H37Rv strain (Fig. 1, 2). This insB gene was 
selected as the focus of this study due to its similarity in sequence with the 
well-characterized ESAT-6 antigen, as well as its exclusivity to the K strain. 
The insB gene was chosen for further study because of its similarity in 
sequence with the well-characterized ESAT-6 antigen and of its presence only 
in the K strain. 
 
2. Protein expression and purification 
 
 Following amplification and insertion of the insB gene sequence into 
the pET11a_KB vector (Fig. 3), the plasmid was successfully expressed in E. 
coli BL21(DE3) with a 6  histidine tag. The protein was then affinity 
purified using a Ni-NTA column. The proteins were further purified with 
FPLC and SDS-PAGE confirmed that the recombinant protein was 
approximately 6 kDa in size, similar to ESAT-6 (Fig. 4). 
 
3. Characterization of antibody response in mice to the recombinant InsB 
protein  
 
 Following three antigen immunizations over a two-week period, 
serum samples were obtained from mice prior to the initial immunization and 
approximately two weeks following the last immunization (Fig. 5). A 
significant level of antibody production was seen in both mice immunized 
with ESAT-6 and with the K-specific InsB protein (P < 0.01). Analysis with a 
paired T-test showed a significance of P < 0.001 for ESAT-6 and P < 0.0001  
 


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Figure 1. Genetic map of the region containing the ESAT-6 and CFP-10 
like proteins in the M. tuberculosis H37Rv and K strains. The 5.7 kb 
insertion region found only in the K strain is indicated by the purple bar. InsB 
is found in this insertion, while the K strain ESAT-6 protein is found outside 
the inserted sequence. 
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Figure 2. Alignment of InsB compared with related proteins in the family 
and ESAT-6 of M. tuberculosis H37Rv. Sequence analysis of the K-specific 
InsB protein shows differences only in several amino acids compared to other 
related ESAT-6 like proteins, except the ESAT-6 sequence in H37Rv 
(Rv3875). The alignment of amino acid sequences between ESAT-6 and InsB 
showed only consensus amino acid sequence conservation in each antigen. 
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Figure 3. pET11a_KB vector with insB insertion. A pET11a_KB vector 
containing a T7 promoter was used to deliver antigen sequences. ESAT-6 like 
sequence insB was inserted into the pET11a_KB vector with NdeI and BamHI 
restriction enzymes. 
 
 
 
 
 
 
 
 
 
17 
 
 
 
 
 
 
 
Figure 4. Purification of the recombinant InsB protein expressed in E. 
coli BL21(DE3). (A) Purification of InsB using ÄKTA-FPLC with a MonoQ 
anion exchange column. (B) SDS-PAGE of purified recombinant InsB after 
ÄKTA-FPLC. Lanes: 1, Dokdo-MARK Prestained Broad-range Protein 
Marker (ELPIS Biotech, Daejeon, South Korea); 2, rESAT-6 5 ㎍; 3, rInsB 5 
㎍ (red arrow). 
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for InsB (Fig. 6). ELISA with ESAT-6 protein and sera from InsB mice, and 
vice versa, showed no reactivity. Both ESAT-6 and InsB are immunogenic in 
elicitng humoral antibody responses, however show no cross-reactivity. 
 
4. Cell-mediated immune response in mice 
 
 Splenocytes from mice were isolated two weeks following the third 
and final immunization. Cells were plated and stimulated with antigen 
candidates for 48 hours and the supernatant was stored at -70℃. Supernatants 
were analyzed using a multiplex cytokine analysis kit from eBioscience (San 
Diego, CA, USA) and a BD LSRII flow cytometer (BD Biosciences, San Jose, 
CA, USA). A large IFN-and IL-17 response was seen in mice immunized 
with InsB protein and stimulated with the protein. However, cells stimulated 
with ESAT-6 showed no reactivity. Likewise, for mice immunized with 
ESAT-6, a moderate response in IL-17 and IFN- was seen for those 
stimulated with ESAT-6, while no response was seen in cells stimulated with 
InsB. Both groups of mice exhibited a low level response of IL-2 to the 
respective proteins as well, while there was little or no TNF- or IL-6 
response in either group (Fig. 7). 
 
5. Antibody responses in TB patients 
 
 Plates were coated with either ESAT-6 or ESAT-6 like InsB and 
incubated with human serum samples of 86 active tuberculosis patients from 
Masan National Tuberculosis Hospital in Changwon, South Korea as well as 
40 TB-negative healthy controls. Results were analyzed using the Mann-
Whitney test, and revealed a significant response for both ESAT-6 (P < 
0.001) and the InsB protein (P < 0.0001) (Fig. 8). Little correlation is seen 
between antibody response to ESAT-6 and InsB proteins, indicating a marked 
difference in B-cell epitopes despite their similarity in amino acid sequence. 
The ROC curves for each antigen showed a greater sensitivity and specificity 
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with InsB compared to ESAT-6 in the serum of patients with active TB. The 
AUC value of ESAT-6 and InsB were 0.62 and 0.75, respectively (Fig. 9). 
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Figure 5. Timeline of mouse immunization and splenocyte harvest. 
Immunizations were given subcutaneously three times, two weeks apart. 
Retro-orbital bleedings were performed prior to the first immunization and 
two weeks following the last immunization. Splenocytes were isolated and 
cytokine analyses were conducted two weeks following the final 
immunization.  
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Figure 6. IgG antibody responses determined by ELISA in BALB/c mice 
immunized with ESAT-6 or InsB. Blood drawn from mice retro-orbitally 
was collected prior to initial immunization and 2 weeks following final 
immunization. An enzyme-labeled anti-mouse IgG antibody was used to 
detect antibody levels (circles : serum from InsB immunized mice, rectangles : 
serum from ESAT-6 immunized mice) (** = P < 0.001, *** = P < 0.0001). 
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Figure 7. Cytokine analysis of mice immunized with ESAT-6 or InsB 
protein. Splenocytes from mice immunized with (A) ESAT-6 or (B) InsB 
were stimulated with either medium (RPMI with 10% FBS), ESAT-6, or 
InsB, and analyzed by flow cytometry. 
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Figure 8. Antibody responses to ESAT6 and InsB in sera from TB 
patients and healthy controls determined by ELISA. ESAT-6 and InsB 
show a significant IgG response in serum samples from active tuberculosis 
patients (n = 86) when compared to healthy controls (n = 40) (* = P < 0.05, 
*** = P < 0.0001). 
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Figure 9. Correlation and receiver operating characteristic (ROC) curves 
of the antibody responses to ESAT-6 and InsB. (A) S/P ratios of IgG 
antibodies to ESAT-6 and InsB proteins in TB patients and healthy controls 
(* P < 0.05; *** P < 0.0001). (B) Dispersion diagram of correlation between 
S/P ratios of IgG antibodies to InsB and to ESAT-6 antigens. (C) Receiver 
operating characteristic (ROC) curves against TB patient serum for the 
diagnosis of TB. ROC curves were derived by plotting the relationship 
between the specificity and sensitivity at various cut-off levels. The 
diagnostic accuracy of the test is expressed by the area under the curve 
(AUC). InsB had a larger AUC (0.75) than ESAT-6 AUC (0.62). 
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IV. DISCUSSION 
 
 Identifying new antigen candidates that can detect tuberculosis 
infection is crucial to improving diagnostic methods. The characterization of 
ESAT-6 and CFP-10 was a major step forward in the immunodiagnosis of 
latent M. tuberculosis infection (LTBI). ESAT-6 is able to elicit a strong T 
cell response in patients with active tuberculosis, indicated by elevated levels 
of IFN-. For both its similarity to ESAT-6, as well as its specificity to the K 
strain, InsB was selected for further studies in diagnostic potential. The 
immunogenicity of InsB was approached from both a humoral and cellular 
perspective. 
 Previous studies on the use of the humoral response in evaluating 
tuberculosis infection differ significantly in their conclusions. Some studies 
on ESAT-6 claim that the humoral response is not a particularly accurate 
method of diagnosis, while others believe there is a possible use for antibody 
measurements as an alternative diagnostic method32, 33, 34. Our results showed 
a significant humoral response (P < 0.001) with ESAT-6 in active 
tuberculosis patient serum samples compared to healthy controls. 
Interestingly, a more significant difference between active patients and 
healthy controls was seen with InsB (P < 0.0001). The ROC curve analysis 
demonstrated that the AUC of InsB is approximately 1.2 fold higher than that 
of ESAT-6. Considering the variability in previous experiments, it is difficult 
to draw any conclusion on the efficacy of InsB antibody titers as a diagnostic 
measurement. However, the use of InsB with other antigen candidates to 
establish an antibody profile may prove to be a more accurate method of 
diagnosis and warrants further study34. In our mouse immunization 
experiments, we also saw a significant difference in humoral response 
between serum samples pre- and post- immunization for both ESAT-6 (P < 
0.01) and InsB (P < 0.0001). Though the sample size was too small to 
accurately illustrate the humoral responses to ESAT-6 and InsB, the results 
suggest that the mice used for this cytokine analysis experiment were 
successfully immunized with the antigen candidates. 
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 The cellular immune response to InsB provides more support for its 
case as a diagnostic biomarker. IFN- has been established as a key 
component in controlling tuberculosis, and its up-regulation during M. 
tuberculosis infection has been established in previous studies. IFN- has 
been the foundation for a new generation of diagnostic tests of LTBI such as 
the interferon gamma release assay (IGRA) and is an important indicator for 
any new antigen candidate considered for immunodiagnosis19,35. In our 
experiments, mice immunized with the K-specific InsB antigen showed a 
strong IFN- response, even when compared to those mice immunized with 
ESAT-6, further supporting its potential use as a biomarker for TB. With the 
purification and elimination of endotoxins through FPLC, we assume the 
cytokine release is solely due to stimulation with the target antigens.  
  Interestingly, InsB also showed a strong response upon stimulation 
in another cytokine, IL-17. In response to M. tuberculosis infection, a 
population of distinct IL-17 producing T-cells has been shown to increase. 
The characteristic expression of the chemokine receptor CCR7 in the absence 
of CD45RA by these IL-17 secreting cells suggests a possible role as long-
lived memory cells36, 37. In M. tuberculosis infection, the release of IL-17 by 
CD4+ T cells leads to inflammation, as well as the recruitment of neutrophils 
and granuloma formation. Down-regulation of IL-17 has been shown to 
decrease proper granuloma formation in mice infected with tuberculosis38.  
 IFN- has been shown to have a complicated relationship with IL-17. 
Studies show that IFN- can down-regulate IL-17, thus modulating the 
inflammation response. It has even been suggested that decreases in IFN- 
levels lead to increased tissue damage through the overproduction of IL-1739.  
However, IL-17 has been suggested to have a priming effect for IFN- 
secreting T cells as well. The TH1 memory response was shown to be 
accelerated by IL-17. In an experiment involving mice vaccinated with 
ESAT-6, the recruitment of IL-17 secreting cells preceded the recruitment of 
IFN- cells. Mice with down-regulated IL-17 had difficulty mounting an IFN-
 response, while treatment with exogenous IL-17 restored the recall response 
of IFN- cells in these mice40.  
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 One study suggests that in combination with other cytokine markers, 
levels of IL-17 might be used to distinguish between active and latent TB 
diagnosis, while another indicates varying levels of IL-17 secretion between 
drug-resistant and drug-susceptible strains41,42. IL-17 is an important cytokine 
in M. tuberculosis infection, and a protein that can elicit an IL-17 response 
could contribute to a more detailed diagnosis of M. tuberculosis infection. 
 An IL-2 response was also shown for both ESAT-6 and InsB proteins 
in this study. IL-2 is a strong inducer of T cell proliferation, but moderates the 
immune response by up-regulation of Treg cells as well43. Several papers 
suggest that IL-2 decreases during active disease, while levels increase as 
treatment progresses or in patients with latent TB44, 45.  
 Based on the release of IL-2 and IFN-, it would seem that the 
cytokine response is strongly TH1-based. However, we see little to no 
response in TNF-, a TH1 cytokine thought to regulate type-1 activation46. 
TNF- deficient mice infected with M. bovis BCG were shown to have 
increased tissue damage due to the overproduction of IFN- and IL-12, while 
in human patients anti-TNF- therapy has led to increased cases of 
reactivation46,47. TNF- release was higher in PBMC and macrophages from 
active tuberculosis patients compared to healthy controls upon 
stimulation48,49. However, the study by Takashima, et al. does indicate higher 
levels of TNF-release in newly diagnosed tuberculosis patients versus 
chronic patients, which might explain why we see decreased levels of TNF-
in our mouse model, whose cytokine release profile was analyzed over a 
month after initial injection48. Also, considering the K strain is associated 
with multi-drug resistant cases, a study looking at whole blood samples from 
patients with either multi-drug resistant (MDR) or drug-susceptible 
tuberculosis found a significant decrease in TNF- production in drug 
resistant cases, while comparable levels of IFN-were released in both 
groups50. These factors, along with the fact that our studies were conducted in 
a mouse model with single antigen immunization should be taken into 
account when comparing our results to experiments with human patients. 
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V. CONCLUSION 
 
 In order to find novel antigen candidates that could improve upon 
current immunodiagnostic methods, proteins unique to a specific strain of M. 
tuberculosis, the K strain were searched. An ESAT-6 like K strain-specific 
protein, InsB, was selected for its location in the K strain genome as well as 
its similarity to the ESAT-6 antigen. The immunogenicity of InsB was tested 
in a mouse immunization model as well as human serum samples. 
Immunization with the antigen candidates, followed by ELISA evaluating the 
B cell antibody response as well as flow cytometry analyzing the T cell 
cytokine response were performed. B cell antibody responses were tested for 
in human patient samples as well.  
 The initial characterization of InsB shows potential as a biomarker for 
M. tuberculosis. The cytokine profile elicited by the protein is comprised of 
three major cytokines involved in the anti-mycobacterial response, IL-17, 
IFN-, and IL-2. However, these studies were conducted in a mouse model 
and additional studies in human PBMC would be needed to confirm the 
protein’s cytokine profile in human patients. The ability to elicit a humoral 
response in human serum samples does illustrate the immunogenicity of InsB, 
but again further studies would be needed to solidify its role in TB 
diagnostics. In conclusion, the initial characterization of InsB merits further 
study of the protein candidate as a diagnostic biomarker for M. tuberculosis 
infection and may lead to a more accurate method of diagnosis, particularly 
for TB patients in South Korea. 
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ABSTRACT (IN KOREAN) 
 
결핵균 K 균주 InsB 항원의 발굴과 면역진단 유용성 분석 
 
 
<지도교수 조상래> 
 
연세대학교 대학원 의과학과 
 
박 재 욱 
 
 
 
 
 
결핵은 결핵균(Mycobacterium tuberculosis)에 의해 유발되는 만성 
감염 질환으로 세계보건기구(WHO) 보고에 의하면 세계 인구의 3분의 
1이 결핵균에 감염되어 있을 정도로 주요한 질병 중 하나이다. 결핵의 
효과적인 치료 및 예방을 위해서는 정확하고 신속한 진단법의 개발이 
필요하다.  
본 연구에서는 최근 국내에서 발생한 결핵 집단감염사례와 결핵 
재발환자에게서 높은 빈도로 분리되는, 결핵균 K 균주의 특이적인 
항원을 발굴하고 그 특성을 규명하여 면역진단항원으로서의 유용성을 
평가하고자 하였다.  
이를 위해 결핵균 H37Rv 표준 균주와 K 균주의 유전체 비교 분석을 
하여 K 균주에서 5.7 kb 의 유전자 삽입부분을 확인하였고, 이 부위에 
삽입되어 있는 여러 개의 ORF 들 중에 현재 IFN- release assay (IGRA) 
결핵 검사법에 이용되고 있는 ESAT-6 항원과 유사한 아미노산 
염기서열을 가진 insB 유전자가 삽입되어 있음을 확인하여 이를 
연구대상 유전자로 하였다.  
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InsB 단백질의 면역원성을 확인하기 위하여 insB 유전자를 대장균 
내에서 발현시키고 Ni-NTA affinity chromatography 와 FPLC 방법으로 
정제하였다. ESAT-6 단백질 또한 같은 방법으로 재조합단백질로 
생산하여 실험 대조군으로 하여 마우스 면역 모델과 사람의 혈청을 
이용한 실험을 진행하였다. 
InsB와 ESAT-6 재조합단백질을 마우스에 각각 2주 간격으로 3회 
면역시킨 후 얻은 혈청에서 ELISA 를 이용하여 각 항원에 대한 IgG 
항체를 검출한 결과 교차 반응 없이 높은 항체가를 확인하였고, InsB 
면역 마우스에서의 반응(P<0.0001)이 ESAT-6 면역 마우스에서의 
반응(P<0.01)보다 통계적으로 유의함을 확인하였다. 또한 각 항원을 
면역시킨 마우스에서 비장세포를 분리한 후 각 항원을 자극시켜 
분비되는 cytokine 들을 ELISA 를 이용하여 분석한 결과, 두 그룹간에 
교차 반응 없이 각 항원에 대해 특이적으로 cytokine이 분비되었고, 특히 
InsB 면역 마우스에서 ESAT-6 면역 마우스에서보다 많은 양의 IFN-γ, 
IL-17 그리고 IL-2 가 분비됨을 확인하여 InsB 단백질이 결핵 
진단면역항원으로서 이용될 수 있는 가능성을 확인하였다.  
실제로 국내의 결핵환자로부터 얻은 86 개의 혈청과 40 개의 
건강인의 혈청에서 InsB와 ESAT-6 항원에 대한 IgG 항체를 검출한 결과, 
두 항원 모두 높은 민감도와 특이도를 보여 혈청진단항원으로서 사용될 
수 있는 가능성을 확인하였다. 특히 ROC 곡선으로 분석한 결과로 
미루어 보아 InsB 항원(AUC=0.75)이 ESAT-6 항원(AUC=0.62)보다 
혈청진단에 더 적합함을 알 수 있었다. 
본 연구 결과는 국내 임상 분리 균주인 K 균주의 특이적인 InsB 
항원을 발굴하여 면역원성을 확인하였으며, 국내 결핵환자를 진단하기 
위한 면역진단항원으로서 사용할 수 있는 가능성을 제시하였다. 추후에 
보다 많은 환자의 검체를 대상으로 InsB 항원의 유용성을 평가하여 결핵 
면역진단방법에 적용될 수 있을 것으로 기대된다.                                                                                                                                                                                                                                                                   
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